Protagonist Therapeutics Inc (PTGX)

Operating profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Operating income (ttm)	US$ in thousands	252,843	149,112	152,239	148,678	-93,652	-153,217	-147,194	-146,283	-131,373	-131,873	-133,496	-122,935	-125,845	-107,659	-81,505	-68,840	-64,516	-62,985	-72,380	-85,570
Revenue (ttm)	US$ in thousands	434,433	323,795	319,120	314,953	60,000	0	0	859	26,581	35,198	45,484	46,890	27,357	24,390	27,218	31,170	28,628	25,697	16,724	2,318
Operating profit margin		58.20%	46.05%	47.71%	47.21%	-156.09%	—	—	-17,029.45%	-494.24%	-374.66%	-293.50%	-262.18%	-460.01%	-441.41%	-299.45%	-220.85%	-225.36%	-245.11%	-432.79%	-3,691.54%

December 31, 2024 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $252,843K ÷ $434,433K
= 58.20%

Protagonist Therapeutics Inc's operating profit margin has exhibited significant fluctuation over the analyzed periods. From March 31, 2020, to September 30, 2022, the company consistently reported negative operating profit margins, with values ranging from -220.85% to -494.24%. These negative margins suggest that the company's operating expenses exceeded its revenues during these quarters.

During the subsequent quarters, the operating profit margin improved notably. By December 31, 2024, Protagonist Therapeutics Inc achieved a positive operating profit margin of 58.20%. This turnaround indicates that the company was able to effectively control its operating expenses and generate operating profits relative to its revenues.

The spike in the operating profit margin to -17,029.45% on March 31, 2023, is an outlier that may have been influenced by extraordinary expenses or accounting adjustments during that period. The subsequent improvement in profitability and the attainment of positive operating profit margins demonstrate a positive trend for the company's operational performance.

Overall, the trend in Protagonist Therapeutics Inc's operating profit margin reflects a transition from significant losses to profitability. It is essential for the company to sustain this positive momentum and continue optimizing its operational efficiency to ensure long-term financial health and viability.